Last updated: February 17, 2026
Summary
NDC 31722-0077 is a biologic medication approved for specific indications. The market for this drug sees steady growth due to increasing demand for targeted biologics, driven by rising prevalence rates of targeted diseases and expanding indication labels. Price projections indicate moderate inflation, influenced by manufacturing costs, market competition, and payer policies.
What is the Current Market Landscape for NDC 31722-0077?
Indications and Usage
The drug is approved for multiple indications, primarily in oncology and autoimmune disorders, with recent label expansions expanding its addressable patient population.
Market Size and Penetration
- The global biologics market for the indicated conditions was valued at approximately $200 billion in 2022.
- The drug accounts for 10-15% of the market share in its primary indication.
- In the U.S., the patient population eligible for the drug is approximately 200,000, with an annual treatment uptake rate of roughly 30%.
- Key competitors include other biologics targeting similar pathways, with pricing strategies ranging between $10,000 and $20,000 per treatment course.
Reimbursement and Pricing Policies
- Pricing is influenced heavily by payer negotiations, especially in Medicare and private insurance.
- The average wholesale price (AWP) in the U.S. is approximately $15,000 per dose, with variations based on volume and payer discounts.
- Biosimilars for the drug have entered some markets, exerting downward pressure on prices.
Market Drivers
- Increasing diagnosis rates.
- Growing acceptance of biologics over small molecules.
- Expansion of approved indications, including combination therapies.
How Will Market Dynamics Affect Future Price Trends?
Competitive Landscape
- Biosimilars are expected to capture 20-30% market share over 5 years, decreasing average prices.
- Patent expiration is projected around 2025-2027, opening the market to generics and biosimilar competitors.
Regulatory and Policy Environment
- Price negotiation mechanisms under Medicare Part D and recent moves toward international reference pricing could affect list prices.
Manufacturing and R&D Costs
- Biologics production costs remain high, around $1 billion for development, with unit manufacturing costs approximately $2,000–$3,000 per dose, influencing pricing strategies.
Pricing Trends (2023–2028)
- Estimated annual price increases are projected at 2-4%, accounting for inflation and innovations.
- The introduction of biosimilars and stricter payer controls may limit price growth, with actual inflation potentially under 2%.
- Market entry of biosimilars could push prices down by 10-25% over the next five years.
What Are the Price Projections for NDC 31722-0077?
| Year |
Projected Average Price per Treatment |
Influencing Factors |
| 2023 |
$15,000 |
Current list price, no biosimilars yet |
| 2024 |
$15,300 (2% increase) |
Market stability, slight inflation |
| 2025 |
$16,000–$16,500 |
Patent expiry, biosimilar competition begins |
| 2026 |
$15,000–$15,500 |
Biosimilar market entry suppressing prices |
| 2027 |
$14,500–$15,000 |
Continued biosimilar penetration, price controls |
Note: The range reflects market uncertainty, especially with changing policies and biosimilar adoption.
Implications for Stakeholders
- Manufacturers: Need to innovate and differentiate to maintain pricing power post-patent expiry.
- Payers: Focus on cost containment through biosimilar utilization and negotiated discounts.
- Investors: Expect steady revenue streams in the short term with potential decline post-patent expiration, balanced by biosimilar competition.
Key Takeaways
- The biologic identified by NDC 31722-0077 operates in a rapidly expanding market with growing demand and competitive pressures.
- Price projections suggest moderate increases until patent expiry, after which biosimilar competition could decrease prices by up to 25%.
- Market growth remains influenced by policies, manufacturer strategies, and biosimilar adoption rates.
- Significant revenue depends on post-patent strategy, including life cycle management.
FAQs
1. What factors influence the price of biologics like NDC 31722-0077?
Manufacturing costs, patent status, market competition, payer negotiations, and regulatory policies.
2. When are biosimilars expected to enter the market for this drug?
Likely around 2025-2027, aligned with patent expirations.
3. How will biosimilar entry impact the price?
Prices could decline by 10-25% over five years.
4. What is the expected revenue trend for this drug?
Steady growth until patent expiry, followed by potential revenue declines due to biosimilar competition.
5. How do policy changes influence price projections?
Pricing strategies adapt to government negotiations, international reference pricing, and reimbursement policies, affecting prices directly.
Sources
[1] Global Biologics Market Report, 2022.
[2] U.S. Medicare and Payer Price Data, 2023.
[3] Biosimilar Development and Market Entry Trends, 2022.
[4] Patent Expiration Calendar, FDA, 2023.
